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Purpose: Inter-patient variations in tumour growth rate are usually interpreted as
biological heterogeneity among patients due to, e.g., genetic variability. However,
these variations might be a result of non-exponential, e.g. the Gompertzian, tumour
growth kinetics. The aim was to study if the natural tumour growth deceleration,
i.e. non-exponential growth, is a dominant factor in such variations.
Materials and methods: The correlation between specific growth rate (SGR) and
the logarithm of tumour volume, Ln(V), was calculated for tumours in patients with
meningioma, hepatocellular carcinoma, pancreatic carcinoma, primary lung cancer,
post-chemotherapy regrowth of non-small cell lung cancer (NSCLC), and in nude
mice transplanted with human midgut carcinoid GOT1, a tumour group which is
biologically more homogeneous than patient groups.
Results: The correlation between SGR and Ln(V) was statistically significant for
meningioma, post-chemotherapy regrowth of NSCLC, and the mouse model, but not
for any other patient groups or subgroups, based on differentiation and clinical
stage.
Conclusion: This method can be used to evaluate the homogeneity of tumour
growth kinetics among patients. Homogeneity of post-chemotherapy regrowth
pattern of NSCLC suggests that, in contrast to untreated tumours, the remaining
resistant cells or stem cells (if exist) might have similar biological characteristics
among these patients.
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Mathematical modelling of tumour growth can provide not only key insights into tumour
biology but also tools for, e.g., optimization of screening programs, cancer patient
prognosis [1], scheduling of chemotherapy [2], and assessment of tumour spread [3,4].
For example, Norton et al. showed that, considering the mathematical growth model of
breast cancer tumours, patients must be treated with condensed-dose chemotherapy, and
a clinical trial showed the significant benefit for the patients treated with the new method
compared with the patients treated with the standard treatment [5,6].
However, one of the main limitations for using tumour growth rate in patient studies
is that therapy is usually started soon after diagnosis and the natural growth of
tumours can be followed only for a limited period of time, during which the growth of
tumours is usually well described by the exponential model. Tumour volumes are© 2014 Mehrara and Forssell-Aronsson; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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resonance imaging (MRI) slice, multiplying the measured area with slice thickness, and
adding all volumes together. There are, therefore, uncertainties involved in estimated
volumes in form of intra- and inter-investigator variations of estimated volumes. How-
ever, growth rate of exponentially growing tumours can be quantified with tumour
volume doubling time (DT), given in days or months. However, the specific growth rate
(SGR) of tumours, given in, e.g. percent per day, is mathematically more accurate and
biologically more relevant than DT for quantification of tumour growth rate [7,8]. If
the tumour volume is measured at times t0 and t, the following equation can be used
for calculation of SGR [7]:
SGR ¼ ln V=V0ð Þ
t ‐ t0
; ðAÞ
where V0 and V are the volume of tumour at t = t0 and t, respectively.
According to the exponential model, the growth rate, i.e. SGR, is constant and inde-
pendent of tumour age or volume. However, studies have shown that tumour growth
rate may decelerate as tumour grows [9-11]. Growth deceleration has been observed in
animal models [12], for solid tumours in clinical studies [13,14], and in leukaemia [9].
Growth deceleration is attributed to several factors, including prolonged cell cycle time,
reduced growth fraction, decreased availability of oxygen [15], decreased cell prolifera-
tion rate with increased cell loss rate [16], tumour-related systemic factors [17], and
allometric growth control [18]. Regardless of the mechanism of growth deceleration, a
number of non-exponential growth models are available in the literature [19], among
which the Gompertzian model is widely used. According to the Gompertzian growth







where SGR0 is the initial growth rate of tumour at t = t0 and λ is the growth deceler-
ation constant.
Fitting the Gompertzian model to the natural growth of tumours needs at least three
tumour volume values measured on occasions spread over a relatively long period of
time, which is rarely obtainable in clinical observations. We have previously developed
a method for estimation of growth deceleration constant, λ, from the linear regression
of SGR with the logarithm of tumour volume [20]:
SGR ¼ SGR0‐λ ln V=V0ð Þ ðCÞ
The above equation enabled us estimating the growth model, including Gompertziangrowth deceleration constant in Equation B (λ) and formation times of metastases in
individual patients.
Tumour response to a specific treatment varies largely among patients. Beside other
biological factors, tumour growth kinetics is important for how a tumour responds to
therapy [21,22]. Tumour volume at base line and its growth rate have both been shown
to be correlated with tumour response to therapy. Different factors are responsible for
the varying tumour growth rates among patients, e.g., genetic factors, microenviron-
ment in host tissue and growth deceleration as tumours grow. Furthermore, measure-
ment uncertainties may also influence the reported variation in growth rate.
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of tumours indicates that tumours probably follow the same growth curve and the
difference in their growth rate is a result of difference in their volume. In other words,
such a correlation is a measure of similarity of growth pattern among tumours, e.g., in
a group of patients. Then, a unique curve can describe the growth of all tumours in the
group, e.g., the curve that we derived for growth of liver metastases from a primary
ileum carcinoid in a previous article [20].
The aim of this study was to assess the homogeneity of the growth kinetics of
tumours of the same type in a population of patients. Data from different groups of
patients, including meningioma, hepatocellular carcinoma, pancreatic carcinoma, and
primary lung cancer, were analysed. The model was also applied to data from a mouse
model bearing transplanted human midgut carcinoid GOT1 tumours, a tumour group
which is biologically more homogeneous than patient groups.Materials and methods
Calculation method
SGR was calculated for each pair of tumour volume measurements using Equation A.
Correlation between SGR and ln(V) was calculated between all SGR values and their
corresponding tumour volume, i.e., the geometric mean of the two volumes used for
calculation of SGR.Clinical data
Data from clinical studies were retrieved from the literature based on the availability of
tumour volume estimates and corresponding measurement time intervals. Tumour
volumes were estimated by delineating tumours in computed tomography (CT) and/or
magnetic resonance imaging (MRI) slices and multiplying the measured area with slice
thickness. Correlation between SGR and the logarithm of the volume of tumours was
calculated for the following types of tumours.Lung cancer
Data on the growth of non-small cell lung cancer (NSCLC) tumours in 18 patients
were used [23]. Tumour growth was measured between the end of induction chemo-
therapy and the start of radiation therapy. The study showed that the regrowth of
tumours after induction therapy (mean DT = 46 days, median DT = 29 days) was much
faster than the untreated tumour growth rate found in the literature (mean DT range:
102–452 days). Of the potentially curable patients 41% became incurable in the waiting
period between chemo- and radio-therapy. Tumour DT was shorter for smaller
tumours compared to large tumour. Considering the fast regrowth of NSCLC tumours
after induction chemotherapy, they recommended diminishing the time interval
between chemo- and radiotherapy to as short as possible [23].
Another set of data was found for the growth rate and characteristics of small periph-
eral lung tumours as they appear on CT images. The tumour types included were
rapidly growing (DT < 150 days) small cell lung cancer, adenocarcinoma, and squamous
cell carcinoma tumours [24].
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Data for untreated pancreatic carcinoma in nine patients who underwent serial exami-
nations by helical computed tomography was used for calculations [25]. The mean DT
of the nine primary lesions was 159 days (median 144 days). Survival time was signifi-
cantly correlated with DT.Hepatocellular carcinoma
The growth of hepatocellular carcinoma (HCC) was studied in 11 untreated patients
where serial CT or MRI images were available (16 tumours in total) [26]. Calculated
DT value range was 17.5-541 days and the mean DT was 127 days. DT was related to
baseline volume as DT = 114 × (baseline volume)0.14. This study showed that smaller
tumours had shorter DT values, i.e. grew faster, than larger tumours and, therefore,
may require shorter follow-up time to observe progression [26].
In an analyses of data from 34 HCC patients, the growth rate of most tumours could be
estimated properly only using histological parameters, e.g. Ki-67index, apoptotic index,
and histologic grade, available at a single time point (DT range was 17–274 days) [27].
We determined SGR and tumour volumes based on data in Table 1 in that article [27].
Another data set on HCC included tumours less than 3 cm in diameter at first obser-
vation in 21 patients [28]. The natural progression of each lesion (DT) was observed by
ultrasonography [28]. They concluded that data from cell kinetic parameters and histo-
logical grade are useful for estimating the natural growth rate of HCC. We determined
SGR and tumour volumes based on data in Table 1 in that article [28].Meningioma
The natural history of incidental meningiomas was studied in asymptomatic patients
[29]. Average tumour volume was 9 cm3 and DT ranged from 1.27 to 143 years (mean,
21.6 y). DT was shorter for younger patients, but was not correlated with tumour size.
We determined SGR and tumour volumes based on data from that article [29]. The
relatively large number of data included enabled us dividing tumours into two groups
and comparing SGR between large and small tumours.Mouse model of human midgut carcinoid, GOT1
In order to test the validity of our method, the correlation between SGR and ln(V) was
studied on tumours in the GOT1 nude mouse model (human midgut carcinoid
tumours), which should biologically be more homogeneous compared with patients
[30]. Data from 57 mice was gathered and the natural growth of tumours was followed
for several weeks before any treatment.Statistical analyses
To test the significance of correlations, the t-values for Pearson correlation were calcu-
lated and then converted to p-values using one tailed T.DIST function in Microsoft
Excel. P-value < 0.05 was assumed to be statistically significant. All patient data used in
this study were retrieved retrospectively from already published articles. This type of
information is exempt from ethical approval. The animal experiments were approved
by the Ethical Committee for Animal Research at University of Gothenburg.
Table 1 Correlation between the specific growth rate, SGR, and the logarithm of tumour volume in groups of patients diagnosed with the same type of
tumour






DTe (days) Relative uncertainty
of volume estimation (%)
Meningioma Nakamura et al. [29] 41 0.2424 0.0005 1230 0.71 0.04 105 1733 37
Hepatocellular carcinoma Nakajima et al. [27] 34 0.038 NS (0.13) 128 2.4 1.30 73 53 86
Saito et al. [28] 21 0.0623 NS (0.14) 146 1.05 0.50 47 139 24
Taouli et al. [26] 16 0.0014 NS (0.89) NA NA 0.90 115 77 NA
Pancreatic carcinoma Furukawa et al. [25] 9 0.0248 NS (0.34) 295 2.13 0.50 58 139 60
Primary Lung Cancer Wang et al. [24] 12 0.1619 NS (0.19) 365 4.21 0.80 36 87 74
El Sharouni et al. [23] 18 0.2713 0.026 48 1.94 2.80 73 25 69
REGROWTH
n: number of tumours.
R: correlation coefficient. Median time interval is calculated from measurement time intervals between the first and the second tumour volume measurements. NA: not available. NS: not statistically significant
(p-values in parentheses). DTe: equivalent doubling time. DTe and uncertainty calculations were done according to previously published methods [7]. Regrowth in the last row means that the calculation has been
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The correlation between SGR and the logarithm of the volume of different types of
tumours are shown in Figure 1 and Tables 1, 2 and 3. The correlation was statistically
significant for meningiomas [29] and regrowth of non-small cell lung cancer tumours
after induction chemotherapy [23]. The correlation was not statistically significant for
the other patient groups and subgroups of tumours. The difference between the growth
rate of the large and small tumours in meningioma group was statistically significant
(p < 0.001), with higher SGR for smaller tumours (Figure 2). Mean SGR was 20%/y and
6%/y for small tumours (n = 20) and large tumours (n = 21), respectively.Figure 1 Regression of specific growth rate, SGR, with the logarithm of tumour volume for
post-chemotherapy regrowth of NSCLC (p < 0.03) and pre-treatment growth of meningioma tumours
(p < 0.01), primary lung cancer (NS), pancreatic carcinoma (NS), hepatocellular carcinoma (NS), and
human carcinoid GOT1 tumours in the mouse model (p < 1E-11). NS: Not statistically significant.
Table 2 Correlation between the specific growth rate, SGR, and the logarithm of tumour
volume in hepatocellular carcinoma patients
Tumour type Group n R2 p-value
Hepatocellular carcinoma,
Nakajima et al. [27] WD 19 0.001 0.5
MD 9 0.063 0.3
PD 6 0.441 0.1
CS I 17 0.040 0.2
CS II 15 0.009 0.4
WD & CS I 8 0.030 0.3
WD & CS II 10 0.001 0.5
Tumours were grouped according to differentiation and clinical stage. None of the correlations were significant. WD: Well
differentiated. MD: Moderately differentiated. PD: poorly differentiated. CS: Clinical stage. n: number of tumours. R:
correlation coefficient.
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statistically significant for data from nude mice bearing GOT1 tumours (p < 1E-11)
(Figure 1).Discussion
Accurate quantification and analyses of the tumour growth rates is essential for under-
standing the biological variance of human cancers [31]. Differences in the observed
growth rates of tumours of the same type in a population of patients can be due to: (a)
measurement uncertainties, (b) growth deceleration with increasing tumour volume, or
(c) other biological differences between tumours, e.g., their location and microenviron-
ment. With regard to measurement uncertainties, we previously showed that SGR is
the tumour growth rate measure that is least influenced by measurement errors, com-
pared to other growth rate measures, e.g., tumour volume doubling time (DT) [7]. We
also showed that SGR is least affected by variances due to biological factors [8]. In the
present study, focused on the growth deceleration in tumours, we used the relation
between SGR and the logarithm of tumour volume to assess the contribution of growth
rate decline in the observed variances in tumour growth rate found in the selected
clinical studies. It should be noted that the limited amount of data on natural tumour
growth available makes this type of studies difficult.
Expected highly significant negative correlation between SGR and the logarithm of
tumour volume in the mouse model (which should be biologically more homogeneous
compared to tumours in groups of patients) showed that the presented method is aTable 3 Correlation between the specific growth rate, SGR, and the logarithm of tumour
volume in hepatocellular carcinoma patients
Tumour type Group n R2 p-value
Hepatocellular carcinoma,
Saito et al. [28] WD 15 0.088 0.1
MD 6 0.007 0.4
Tumours were grouped according to differentiation level. None of the correlations were statistically significant. WD: Well






















Figure 2 Frequency distribution of specific growth rate, SGR, in two groups of small (n = 20) and
large (n = 21) meningioma tumours. Mean SGR was 20%/y and 6%/y for small and large tumours,
respectively (p < 0.001).
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in tumour growth rates observed among patients.
A significant correlation between SGR and the logarithm of tumour volume in a
group of tumours also indicates that the smaller tumours represent the growth of larger
tumours when they were of small size and vice versa. This provides the possibility for
further development of mathematical models for elaborating this correlation in more
accurate efficacy assessment of new drugs or combination of treatments. However, lack
of correlation between SGR and the logarithm of tumour volume indicates that
biological factors other than growth deceleration are more important for explaining the
differences in the tumour growth rate observed in a population of patients with the
same tumour type. These tumours may grow exponentially with different growth rates,
or according to the Gompertzian model, and the model constants, SGR0 and λ, are
heterogeneously distributed among tumours [20].
In this study, the correlation between SGR and the logarithm of tumour volume was
statistically significant for the growth of tumours in meningioma patients. Further
analysis by dividing the material into small and large tumours also supported this
result. A similar growth model observed for a group of patients with one tumour type
corroborates that the response rate in this group might be a suitable measure to assess
the efficacy of novel treatments. The correlation between tumour growth rate and the
logarithm of its volume was, however, not statistically significant for the studied patient
cohorts with hepatocellular carcinoma, pancreatic carcinoma, and primary lung cancer.
This result was expected for the primary lung cancer cohort, since that included differ-
ent types of lung cancer. A lack of correlation indicates that the growth of these types
of tumours varies between patients with similar tumour type and, therefore, growth
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treatment of patients with these types of tumours both in clinical trials and for individ-
ualized therapy planning.
However, in the present study we were in general not able to include factors such as
histologic grade and differentiation in our analyses, due to the limited number of
tumours/patients or lack of information for other types of tumours. The only exception
was for hepatocellular carcinoma, where subgroups could be categorized according to
their differentiation level and clinical stage. However the correlation between tumour
growth rate and the logarithm of its volume was not statistically significant for any of
the two patient cohorts studied. It would otherwise be possible that stratification of the
tumours according to, e.g., histopathological information would have given better cor-
relation within subgroups of each tumour type. The result of the animal study indicates
such a situation.
Nevertheless, the significant correlation between tumour growth rate and the loga-
rithm of its volume for regrowth of primary lung cancer tumours after chemotherapy
was interesting, because this can be interpreted as homogeneity of these tumours
among patients. Post-chemotherapy tumours consisting of resistant cancer cells or
cancer stem cell clones (if exist) of non-small cell lung cancer might be more homo-
geneous in terms of cellular and histological characteristics and, therefore, respond
more similarly to therapy. Such information is valuable for further treatments in, e.g.,
neoadjuvant therapy.
The main difference between meningioma and other types of tumours in the present
study is that meningiomas are benign. It is possible that the reason for meningioma
being the only tumour type that gave significant correlation between tumour size and
tumour growth rate in the patient cohorts is that it is benign, with low proliferation
rate and histologically more homogeneous than malignant tumours.
In the original study on meningioma, no correlation between tumour DT and its
volume was found [29]. On the other hand, we found strong correlation between SGR
and the logarithm of tumour volume, a correlation that, by definition, is the accurate
measure of growth rate deceleration as tumour grows. The significant difference
between growth rate of small and large tumours also supported our result. This is in
line with our previous study where we showed that using DT for quantification of
tumour growth rate can result in wrong conclusions [8]. This emphasizes again the
need for developing new accurate mathematical tools to analyse clinical data.
In conclusion, the presented method, i.e. estimation of the Gompertzian growth
deceleration constant using limited clinical data, can be used to evaluate the homo-
geneity of tumour growth pattern among patients. Tumour growth kinetics was largely
heterogeneous among patients with the same type of tumour, except for the menin-
gioma group. This implies that the tumour growth kinetics in each patient should be
considered in efficacy assessment of new drugs and for optimization of treatment in
individual patients using, e.g., the tumour response model in ref [21,22]. Furthermore,
homogeneity of post-chemotherapy regrowth pattern of non-small cell lung cancer
tumours suggests that, in contrast to pre-treatment tumours, the remaining resistant
cancer cells or cancer stem cells (if exist) might have similar biological characteristics
among these patients, a factor that should be valuable to consider in, e.g., neoadjuvant
therapy.
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